Heart Test Laboratories (HTL) develops the MyoVista, a technologically advanced medical electrocardiography device that uses standard 12-lead resting ECG protocols plus proprietary informatics to help identify ischemic and other myocardial dysfunctions. MyoVista provides a traditional interpretive ECG alongside additional proprietary analysis and is designed for use in both primary care and hospital settings, featuring a 15.6-inch high-resolution touchscreen and tablet-like user features. HTL is privately held and has been funded by private investors to date. The company completed a $12 million Common Stock private placement that was significantly over-subscribed and will fund the international sales launch, operations, and further clinical work. HTL is hiring sales staff as it prepares for the expected international launch of MyoVista in the first quarter of 2017. The device and corporate focus target earlier identification of heart disease to bridge the diagnostic gap prior to adverse cardiac events.

Total raised

$12M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2017